INTERPACE BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
About Interpace Biosciences
Surgical & Medical Instruments & Apparatus, SIC 3841
Interpace Biosciences, Inc. is a commercial-stage company that provides molecular diagnostic testing and pathology services. The company specializes in evaluating cancer risk for patients with indeterminate biopsies and clinical indications of malignancy. Its commercialized offerings center on tests for thyroid cancer, specifically the ThyGeNEXT oncogenic mutation panel and the ThyraMIR v2 microRNA classifier, which are used in combination to inform surgical and treatment choices. Customers include physicians, hospitals, cancer centers, commercial laboratories, clinics, and pathology groups.
The company conducts clinical laboratory testing at a CLIA-certified and CAP-accredited facility situated in Pittsburgh, Pennsylvania. Its sales and marketing efforts are focused predominantly within the United States and are supported by a field-based commercial team. Interpace Biosciences maintains its principal executive offices and headquarters in Parsippany, New Jersey.
Summary of the business section of Interpace Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INTERPACE BIOSCIENCES, INC.
- Headquarters
- Parsippany, NJ
- Address
- Waterview Plaza, Suite 310, 2001 Route 46 07054
- Phone
- (412) 224-6100
- Website
- interpace.com
- Employees
- 102, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper, LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- IDXG
- Exchange
- OTC
- Shares outstanding
- 28M, Jul 31, 2026
- Public float
- $2.63M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Apr 22, 2020; 1-for-10 reverse, Mar 31, 2017
- SEC CIK
- 1054102
- EIN
- 22-2919486
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas W. Burnell | CEO, President & Chairman, Director | 2,048,530 |
| Christopher McCarthy | CFO & COO | 323,800 |
| Stephen J. Sullivan | Director | 24,583 |
| Vijay Aggarwal | Director | – |
| Joseph D. Keegan | Director | 17,569 |
| Fortunato R. Rocca | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Burnell | $708.19K | $708.19K | $468.27K | $118 | – |
| FY2024 Mr. Burnell | $703.79K | $703.79K | $434.53K | $260 | – |
| FY2023 Mr. Burnell | $678.41K | $608.07K | $332.04K | $104 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 2, 2026, we had 102 full time employees and 102 total employees.”
Corporate history
Events identified from SEC filings